Answers are grounded in this paper and cite their sources.
To explore the clinical and pathological characteristics, immunophenotypes, and molecular genetic features of invasive male breast cancer. The clinicopathological data of 55 male patients with invasive breast cancer were analyzed. Surrogate subtyping of evaluable patient samples was performed using immunohistochemistry (IHC) to determine the expression of ER, PR, HER2, and Ki-67. Diagnostic next-generation sequencing (NGS) reports were available for 34 patients, including 23 with paired tumor–blood testing and 11 with blood-only testing, using report-labelled 511- or 539-gene assays. Among the 55 patients, the median age was 67 years (27–87 years), with a median tumor size of 1.7 cm (0.12–5.5 cm). Most tumors were grade 2 (81.8%). Among 51 cases with evaluable IHC data, 20 (39.2%) were luminal A-like, 30 (58.8%) luminal B-like and one (2.0%) hormone receptor-negative/HER2-positive. Genetic reports were available for 34 patients. Somatic PIK3CA variants designated oncogenic in the diagnostic summaries were reported in 6 of 23 paired-tested cases (26.1%). Pathogenic germline variants of BRCA2 and CHEK2 were reported in 4 (11.8%) and 2 (5.9%) of 34 blood-tested cases, respectively. FGFR1, ERBB2, MYC, CCND1, FGFR2 and AKT3 amplifications were reported in 4 (17.4%), 2 (8.7%), 2 (8.7%), 1 (4.3%), 1 (4.3%) and 1 (4.3%) of 23 paired-tested cases, respectively. In males, invasive breast cancer is a rare malignancy that predominantly affects older individuals. Most evaluable cases in this series were hormone receptor-positive according to IHC-based surrogate subtyping. PIK3CA somatic variants, pathogenic germline BRCA2/CHEK2 variants and FGFR1 amplification were recurrent report-documented findings.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: